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Article

Reward Value of Cigarette Smoking
for Comparably Heavy Smoking Schizophrenic,
Depressed, and Nonpatient Smokers
Bonnie Spring, Ph.D.
Regina Pingitore, Ph.D.
Dennis E. McChargue, Ph.D.

Objective: The study goal was to determine whether schizophrenic and depressed smokers perceive the reinforcement value of cigarette smoking differently
from nonpsychiatric smokers who smoke
as heavily.
Method: The authors assessed the preferences for smoking cigarettes versus engaging in other pleasant activities, the
perceived advantages and disadvantages
of smoking, and the amount of reinforcement that would be needed to attain
smoking abstinence among 26 schizophrenic, 26 depressed, and 26 nonpsychiatric heavy smokers.
Results: Both schizophrenic and depressed participants chose smoking as
their preferred activity more often than

nonpsychiatric smokers, and they did not
differ from each other. The patients also
exceeded the comparison group in the
benefits they ascribed to smoking and felt
they would require more incentives to
quit, but they attributed comparable
drawbacks to smoking.
Conclusions: Sc h izop hren ic an d depressed smokers recognize many drawbacks associated with smoking , but
compared to nonpatients who smoke as
heavily, they also perceive more benefits
and find cigarettes more appealing than
alternative rewards. The heightened reward value of smoking warrants attention
in tailoring tobacco control interventions
for schizophrenic and depressed smokers.
(Am J Psychiatry 2003; 160:316–322)

C

igarette smoking remains the greatest preventable
cause of death and disease in the United States (1, 2). After
declining steadily for several decades, the prevalence of
smoking stabilized in 1990 and since has decreased only
minimally (3). The plateau in the smoking rate derives
partly from several subpopulations of recalcitrant smokers who have been unable to quit (4, 5).
Schizophrenic and depressed smokers are two subgroups that have been especially difficult to reach. A decade-long antismoking campaign that made most hospitals smoke-free (6–8) has done little to decrease rates of
smoking by psychiatric patients. Nor have either generic
or selectively targeted treatments achieved notable success in promoting smoking cessation among either
schizophrenic (9–12) or depressed (13, 14) individuals.
Only about 1% of the population is affected by schizophrenia, but the prevalence of nicotine dependence among
schizophrenic people is very high (58%–92%) (15–18). Major depression affects about 15% of the population and has
a smoking prevalence rate of 31%–61% (15, 19, 20), higher
than that for the general population (20%–30%) (3) but
lower than that for schizophrenia. Thus, comorbidity of
nicotine dependence with these two forms of psychopathology affects a substantial segment of the population, adding to health care expenditures (21–23). Higher rates of
smoking in schizophrenia and depression cannot be ex-
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plained by differences in socioeconomic status, occupation, education, marital status, caffeine intake, or institutionalization, because they persist even after the effects of
these confounding variables are taken into account (15).
The influences that make schizophrenic patients especially likely to smoke could be the same ones that lead depressed individuals to smoke, or they could differ. Consequently, we tested two alternative hypotheses: 1) diagnostic
specificity: that schizophrenic patients find smoking more
rewarding than depressed patients, and 2) psychopathologic commonality: that schizophrenic and depressed
smokers find smoking similarly more rewarding than do
comparison smokers without psychiatric disorders other
than nicotine dependence.
The substantially higher prevalence of smoking in
schizophrenia than depression suggests diagnostic specificity, which might reflect schizophrenia’s unique pathophysiology or treatment. For example, schizophrenic patients may smoke to reduce the side effects of neuroleptic
medications (24), although support for that proposition
has been mixed (25–27). Also, schizophrenic patients may
smoke to alleviate negative symptoms (11). Nicotine may
be particularly reinforcing in schizophrenia because it
stimulates the subcortical reward system and the prefrontal cortex, which both appear to be hypofunctional in
schizophrenia (28–30). Through its action at nicotinic
Am J Psychiatry 160:2, February 2003
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cholinergic receptors, nicotine increases firing of dopamine neurons in mesocorticolimbic pathways, enhancing
dopamine release in both the nucleus accumbens and
prefrontal cortex (28). Dopamine deficiency and low metabolic activity in these regions have been linked to the
negative symptoms (29) and sensory gating deficits (31)
that characterize schizophrenia.
Alternatively, smoking might function to ameliorate behavioral and biological vulnerabilities that are shared by
schizophrenic and depressed individuals. For example,
self-administering nicotine through smoking might transiently help to ameliorate anhedonia: a diminished capacity for pleasure that is evident in both schizophrenia and
depression (32, 33). Nicotine’s ability to directly trigger
dopamine release in mesolimbic reward centers may render smoking one of few remaining reinforcers that schizophrenic and depressed patients experience as pleasurable
(34). There are functional interactions between the cholinergic system and other neurotransmitter systems (e.g.,
glutamate, γ-aminobutyric acid [GABA], serotonin) that
are abnormal in the two disorders. Self-administering nicotine may, therefore, serve to medicate affective, cognitive, and behavioral problems that arise from dysfunction
in several neurotransmitter systems (28, 35, 36).
In this study we compared several aspects of the reinforcing value of smoking for schizophrenic, depressed,
and nonpsychiatric comparison subjects. One facet was
the perceived advantages (“pros”) and disadvantages
(“cons”) associated with smoking. We predicted that a decisional “balance sheet” of either the patients generally or
the schizophrenic patients particularly would show that
their perception tipped more strongly than that of comparison subjects toward believing that the pros of smoking
outweigh the cons. We further expected that the biased
decisional balance would result from the perception that
smoking has both more pros and fewer cons than perceived by the comparison subjects. The rationale for predicting greater pros was that smoking should serve as a
potent negative reinforcer particularly for schizophrenic
patients, and perhaps more generally for psychiatric patients, because it dispels troublesome psychiatric symptoms (e.g., negative symptoms and medication side effects
for schizophrenic patients, attentional problems and dysphoric mood for both schizophrenic and depressed patients). The rationale for predicting fewer perceived cons
of smoking was that the cognitive deficits and social isolation that occur especially in schizophrenia but also in depression (37–39) might insulate patients from learning to
fully appreciate the negative consequences of smoking.
In addition to the perceived pros and cons of smoking,
we also evaluated two other aspects of smoking’s reward
value. One was participants’ reported preferences for engaging in smoking rather than alternative pleasant activities. We expected that either the schizophrenic patients
specifically or both psychiatric groups would show greater
than normal preferences for smoking over other activities.
Am J Psychiatry 160:2, February 2003

The rationale was that smoking may remain one of few dependable sources of pleasure by virtue of its ability to directly trigger dopamine release. Finally, we also appraised
reward value by quantifying how much of each of a variety
of rewards smokers felt they would require in order to quit
smoking permanently. We predicted that schizophrenic
patients particularly or patients generally would feel they
needed greater than normal rewards to quit.
To validly test the study hypotheses, the research design
needed to control for smoking rate. Otherwise, apparent
differences between patients and normal subjects could
arise spuriously from the fact that patients, especially
schizophrenic ones, tend to smoke heavily (15). So that
differences between psychiatric and nonpsychiatric smokers would not be attributable to different smoking rates,
we compared psychiatric outpatients to a normal comparison group of firefighters, a group characterized by heavy
smoking (40).

Method
The study had 78 participants: 26 with schizophrenia (disorganized subtype, N=9; paranoid, N=9; catatonic, N=4; undifferentiated, N=4), 26 with major depression (recurrent in all cases), and
26 nonpsychiatric comparison smokers. The schizophrenic and
depressed subjects were outpatients receiving treatment at an urban psychiatric rehabilitation center. All of the schizophrenic patients were taking typical neuroleptics; the depressed patients
were taking either selective serotonin reuptake inhibitors or tricyclic antidepressants. The nonpsychiatric comparison smokers
were employees at a local fire station. The eligibility criteria required that participants be older than 18 years of age, smoke
more than 15 cigarettes per day, and lack evidence of gross cognitive impairment (evidenced by a Mini Mental State Examination
[41] score higher than 24).
A pilot study was conducted to determine whether the schizophrenic and depressed patients could be diagnosed reliably on
the basis of chart review and whether the nonpatients’ screening
interview reports of psychiatric symptoms corresponded to the
results of semistructured interviews. An advanced clinical psychology graduate student administered the patient version of the
Structured Clinical Interview for DSM-III-R (SCID) (42) to seven
schizophrenic patients and five depressed patients from the rehabilitation center and the nonpatient version to five firefighters.
Findings of 100% concordance between the SCID and chart
review diagnoses for the patients and between the SCID and
screening interview diagnoses for the nonpatients supported the
use of screening interview diagnoses, supplemented for patients
by chart review.
Nonpsychiatric comparison smokers were excluded if they
presented evidence of any current or past axis I disorder other
than nicotine dependence. Psychiatric participants were excluded if they exhibited comorbid axis I disorders other than
schizophrenia, depression, and nicotine dependence. Those with
schizoaffective disorder were excluded. The interviewer also assessed demographic and smoking characteristics and administered the Fagerstrom Tolerance Questionnaire (43) to measure
physical dependence on nicotine. After complete description of
the study to the subjects, written informed consent was obtained.
Assessments were usually performed on a single day, during
which participants could take smoking breaks.
Perceived pros and cons of smoking were assessed by a modified 28-item version of the Decisional Balance Scale (44). Particihttp://ajp.psychiatryonline.org
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TABLE 1. Demographic and Smoking Characteristics of Schizophrenic, Depressed, and Nonpsychiatric Heavy Smokers
Patients With
Schizophrenia (N=26)
Characteristic
Age (years)a
Education (years)
Packs smoked per day
Age when smoking began (years)
Score on Fagerstrom Tolerance Questionnaireb
a Significant
b Significant

Mean
40.00
11.81
1.85
15.88
9.04

Mean
35.31
13.21
1.83
14.50
9.00

SD
11.13
2.24
0.84
4.56
1.57

Nonpsychiatric
Comparison Subjects (N=26)
Mean
26.20
12.96
1.81
14.73
7.54

SD
11.69
1.01
0.72
3.64
1.82

difference among groups (F=10.2, df=2, 76, p<0.001).
difference among groups (F=6.6, df=2, 76, p<0.01).

pants indicated their agreement with 14 possible advantages and
14 possible disadvantages of smoking by rating each item 1 (disagree), 2 (agree), or 3 (strongly agree). The scale was altered to
make it more suitable for psychiatric patients by simplifying the
wording, making it appropriate for administration by an interviewer, and adding items to assess positive and negative effects
on psychiatric symptoms (e.g., “When I smoke, I enjoy everything
more in life”; “Sometimes smoking makes me hear noises, voices,
or sounds that other people don’t hear”). Each subscale score
ranged from 14 to 42, and internal consistency was high for both
the pro (Cronbach’s alpha=0.81) and con (alpha=0.82) subscales.
A decisional balance index was also computed by converting the
scores on both subscales to z scores and subtracting the score for
cons from the score for pros (44).
Preferences for engaging in smoking versus other rewarding
activities were measured by a questionnaire developed for this
study. The test required participants to make 15 forced choices
between smoking and a variety of rewards likely to be accessible
and enjoyed by psychiatric patients (e.g., eating their favorite
candy, seeing a movie, receiving a gift). The choice of smoking
was scored as 1; the choice of the other reward was scored as 0.
Scores on the preferences questionnaire ranged from 0 to 15, and
the test exhibited acceptable internal consistency (alpha=0.74).
The magnitude of reward felt necessary for quitting was measured by a rewards questionnaire created for this study. The questionnaire asked how much of each of 15 rewards (e.g., candy, coffee,
money) participants would need to quit smoking permanently.
The amount of each reward was scored from 1 to 7, yielding a total
score ranging from 15 to 105. Higher numbers indicated a need for
more rewards to quit smoking. Further information and copies of
the test instruments are available from the first author on request.

Results
All three groups of participants were nicotine-dependent, heavy smokers who had smoked since their teenage
years (Table 1). Univariate analysis of variance (ANOVA)
detected no differences among the groups in the number
of cigarettes smoked daily. The percentages of women in
the three groups were as follows: schizophrenic, 26.9% (N=
7); depressed, 50.0% (N=13); comparison, 19.2% (N=5);
lambda indicated that the proportion could not be predicted on the basis of diagnostic group. The patients were
older and more physically dependent on nicotine (Table
1), so the analyses accounted for those differences. Age
and Fagerstrom score were treated as covariates in the
analyses of decisional balance, preferences for smoking,
and rewards needed to quit, because the assumptions underlying analysis of covariance (ANCOVA) were met for
these outcomes. ANCOVA could not be used to analyze
pros and cons because the slopes of the regressions pre-
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SD
10.85
2.15
0.85
5.46
1.68

Patients With
Major Depression (N=26)
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dicting these outcomes from age and Fagerstrom score
were not parallel across the groups. Therefore, for the
analysis of pros and cons, age and Fagerstrom score were
transformed to discrete variables and treated as ANOVA
blocking factors, making it possible to examine any interactions with group (45). Age was dichotomized as ≤36
years versus older, and Fagerstrom score was trichotomized as ≤7 versus 8 versus ≥9. Pros and cons were analyzed by two univariate ANOVAs rather than by multivariate analysis of variance, because they were uncorrelated
(r=0.07, df=78). For all analyses, two a priori orthogonal
contrasts examined the alternative hypotheses that the
schizophrenic patients differed from the depressed patients (diagnostic specificity) and that the two patient
groups differed from the nonpatients (psychopathologic
commonality).
Analysis of the decisional balance indexes, controlling
for age and Fagerstrom score, indicated that the groups differed significantly (F=15.2, df=2, 73, p<0.001). Consistent
with psychopathologic commonality, the patients, compared to the normal subjects, attributed relatively greater
advantages than disadvantages to smoking (F=27.9, df=1,
73, p<0.001), and there were no significant differences between the schizophrenic and depressed patients. The positive decisional balances shown by the schizophrenic
(mean=10.31, SD=4.74) and depressed (mean=11.81, SD=
3.29) smokers indicated that both groups appraised the advantages of smoking as greatly outweighing the disadvantages. In contrast, the index approached zero for the nonpsychiatric comparison subjects (mean=0.42, SD=3.52),
indicating that they judged the pros and cons of smoking
nearly equivalent.
As expected, the groups differed significantly on how
strongly they endorsed the pros of smoking (Figure 1), and
there were no interactions with age or Fagerstrom score.
Consistent with psychopathologic commonality, the patients exceeded the comparison subjects in the pros they
ascribed to smoking (F=187.0, df=1, 75, p<0.001). The
scores of the schizophrenic patients (mean=32.85, SD=
3.71) and depressed patients (mean=33.88, SD=3.48) did
not differ significantly and were both higher than that of
the comparison subjects (mean=22.77, SD=2.32). Unexpectedly, the groups failed to differ in their perceptions of
the negative consequences of smoking (comparison:
mean=22.35, SD=2.87; schizophrenic: mean=22.54, SD=
Am J Psychiatry 160:2, February 2003
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FIGURE 1. Degree of Endorsement of 14 Pros and 14 Cons
of Smoking by Schizophrenic, Depressed, and Nonpsychiatric Heavy Smokersa

11

Patients with
schizophrenia (N=26)
Total Rating of Preferences for
Smoking Over Other Rewardsa

Total Rating of Endorsementb

39

FIGURE 2. Degree of Preferences for Smoking Over 15
Alternative Rewards Reported by Schizophrenic, Depressed, and Nonpsychiatric Heavy Smokers

Patients with major
depression (N=26)

34

Nonpsychiatric
comparison
subjects (N=26)

29

c

24

19

14

9

7
b

5

3

1
Pros

Cons

a

Assessed with a modified version of the Decisional Balance Scale
(44).
b 14=disagrees with all 14 pros/cons of smoking, 42=strongly agrees
with all 14 pros/cons of smoking.
c Significant difference among groups (F=75.6, df=2, 72, p=0.0001).

2.45; depressed: mean=22.08, SD=2.84), and there was no
interaction with age or Fagerstrom score. The results,
shown in Figure 1, indicate that the schizophrenic and depressed patients recognized the disadvantages of smoking
as fully as did the nonpsychiatric comparison smokers but
considered them less impressive than the advantages.
Also supporting psychopathologic commonality, both
patient groups exceeded the comparison subjects in their
reported preferences for smoking rather than other pleasant activities, after age and Fagerstrom score were controlled for (Figure 2). Again, there was no difference
between the schizophrenic and depressed patients. As
shown in Figure 2, the average nonpsychiatric comparison
subject chose smoking over other rewards in about 33% of
the 15 choices (mean score=5.27, SD=1.04), whereas the
average schizophrenic and depressed patients preferred
smoking in about 67% of the choices (schizophrenic:
mean=10.42, SD=1.88; depressed: mean=10.04, SD=1.87).
Finally, controlling for age and Fagerstrom, we found
that the groups differed in the magnitude of the rewards
they would find necessary in order to quit smoking (Figure
3). Again, the schizophrenic (mean score=102.65, SD=
2.15) and depressed (mean=102.62, SD=2.52) smokers
failed to differ from each other. Both patient groups felt
that quitting would require substantially more rewards
than did the comparison smokers (mean=69.35, SD=7.93).

Discussion
The results of this study indicate that both schizophrenic
and depressed smokers associate greater advantages and
Am J Psychiatry 160:2, February 2003

Nonpsychiatric
Comparison
Subjects (N=26)

Patients
With Major
Depression
(N=26)

Patients With
Schizophrenia
(N=26)

a

0=choose all other reward options in preference to smoking, 15=
choose smoking in preference to all other reward options.
b Significant difference among groups (F=54.3, df=2, 73, p=0.0001).

reward value with cigarette smoking than do individuals
without psychiatric disorders who smoke as heavily. There
were virtually no differences between the patient groups.
The findings also show that the patients appreciated the
drawbacks of smoking as fully as the nonpsychiatric comparison subjects but considered them outweighed by
smoking’s advantages. In contrast, the comparison subjects perceived the pros and cons of smoking as nearly
equivalent. When asked to choose between smoking and
other pleasant activities, the schizophrenic and depressed
smokers chose smoking twice as often as the comparison
subjects. Finally, the incentives that the patients said they
would need to quit smoking approached the maximal possible reward magnitude, markedly exceeding what the
comparison subjects said they would need.
The rarity of smoking cessation by schizophrenic and
depressed smokers has remained largely unexplained.
Candidate explanations have been that patients 1) have
minimal contact with antismoking messages and little access to smoking cessation treatment, 2) are characterized
by a preponderance of heavy smokers, or 3) experience
nicotine effects on psychopathologic vulnerabilities that
render the smoking habit exceptionally rewarding and difficult to break. The current prevalence of nonsmoking environments and media antismoking messages, coupled
with the availability of over-the-counter cessation aids,
make it increasingly implausible that psychiatric patients
smoke because they are unaware of the risks or lack access
to cessation resources. Indeed, the current findings contradict that premise, by showing that psychiatric patients
http://ajp.psychiatryonline.org
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FIGURE 3. Amounts of 15 Rewards Considered Necessary
to Quit Smoking by Schizophrenic, Depressed, and Nonpsychiatric Heavy Smokers
115

Total Amount of Rewards
Needed to Quit Smokinga

95

75

b

55

35

15

Nonpsychiatric
Comparison
Subjects (N=26)

Patients
With Major
Depression
(N=26)

Patients With
Schizophrenia
(N=26)

a

15=minimal other rewards needed to quit smoking (needs only 1
unit of each of 15 rewards), 150=maximal other rewards needed to
quit smoking (needs 10 units of each of 15 rewards).
b Significant difference among groups (F=12.5, df=2, 73, p=0.0001).

appreciate the disadvantages of smoking as adequately as
smokers without major psychopathology.
These are, to our knowledge, the first findings to demonstrate that both schizophrenic and depressed patients attribute greater-than-normal reward value to cigarette
smoking and that the difference is unlikely to be explained
by variation in nicotine exposure. All three study groups, including the nonpsychiatric comparison subjects, smoked
heavily (nearly two packs per day), and there was no difference among them in the amount smoked. It is interesting
that, despite smoking equally heavily, the patients reported
features (such as smoking soon after awakening) that suggest greater physical dependence on nicotine. That patients
apparently exhibit greater nicotine dependence than nonpsychiatric comparison subjects, even given seemingly
comparable nicotine exposure, is intriguing. Nevertheless,
we think it unlikely that group differences in nicotine dependence can explain the greater reward value of cigarettes
for smokers with other psychiatric disorders because our
analyses controlled for them.
The lack of difference between schizophrenic and depressed smokers was surprising, especially given the
higher prevalence of smoking usually observed among
schizophrenic patients. Two explanations suggest themselves. One is that, by studying only heavy smokers, we selected depressed patients who were unrepresentative of
that disorder but held many sociodemographic features in
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common with schizophrenic patients. An alternative explanation that seems more likely is that there may be
genuine commonalities in what hooks schizophrenic and
depressed smokers to their cigarettes. Plausibly, schizophrenic and depressed individuals share certain neurobiological features, either premorbidly or as a consequence
of illness, medications, comorbid addictions, or even
chronic nicotine exposure, that render nicotine a particularly appealing drug to self-administer. Earlier we posited
that nicotine’s ability to trigger dopamine release in mesolimbic reward centers might render smoking one of the
few reinforcers able to overcome the anhedonia that characterizes schizophrenia and depression (28). Beneficial effects on other core affective and cognitive psychopathologic vulnerabilities may also occur (46), mediated by
nicotine’s effects on serotonin, glutamate, GABA, and
acetylcholine (36).
Certain limitations of the current study need to be considered. First, the findings can be interpreted only as indicating that cigarette smoking (not necessarily nicotine)
has disproportionate reward value for schizophrenic and
depressed smokers. Laboratory experimental studies are
needed to differentiate between the pharmacological effects of nicotine and the sensory effects of smoking on
perceived reward. Second, the data were based on self-reports provided by psychiatric patients. Can such self-reports, particularly those of patients with schizophrenia,
be considered valid? Some reassurance derives from the
consistent pattern of group differences across all measures of smoking’s reward value, from how closely the reports of the schizophrenic patients resembled those of
the depressed outpatients, and from the fact that all of the
groups seemed well informed of the negative consequences of smoking. Nevertheless, it would be advantageous for the results to be replicated by behavioral protocols not requiring participants to have any insight into
their own motivations (see reference 47). Third, the generalizability of the findings remains unclear. The patients
with psychiatric disorders had relatively high levels of
functioning: the groups included only patients who were
able to live outside the hospital, manage their own appointment schedules, and pass the mental state entry criteria imposed for this study. It cannot be assumed that the
results, perhaps particularly those showing full awareness
of the disadvantages of smoking, would generalize to
more severely impaired patient populations.
The results may have implications for smoking cessation treatment. Research guided by the transtheoretical
model has shown that people progress through a series of
stages in their readiness to initiate change in health-related behavior (48). The patients’ motivational balance
sheet, in which the pros of smoking outweighed the cons,
is typical of people in the precontemplative stage of readiness to quit smoking. Smokers in the precontemplative
stage recognize intellectually that they need to quit, but
they are not actually intending to make an attempt to quit
Am J Psychiatry 160:2, February 2003
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in the foreseeable future. To progress to the stage of contemplation, which involves seriously thinking about making an attempt to quit, the smoker needs to experience a
decline in the perceived advantages of smoking. The
heavy-smoking nonpatient participants in this study differed from the patients in showing a typical motivational
balance for contemplators: one in which the perceived advantages of smoking have lessened and are roughly equivalent to its perceived drawbacks. The contemplator’s likelihood of moving into the stage of preparing to make a quit
attempt will be enhanced by experiences that enhance
feelings of self-efficacy about being able to quit.
Enrollment in smoking cessation treatment has been
shown to be unproductive until a smoker reaches the
stage of at least contemplating, if not actively preparing to
make, a quit attempt (49). If the patients in the current
study are representative of other schizophrenic and depressed smokers in being at a very early stage of readiness
to quit, referral to smoking cessation treatment would be
premature and ineffectual. More appropriate and needed
forms of tobacco control intervention for smokers with
psychiatric disorders may involve motivational interviewing and other brief interventions that overcome barriers to
considering healthy behavior change (50).
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